A 28-Year-Old Patient with Myelodysplastic Syndrome Undergoes Allogeneic Bone Marrow Transplantation

In 2025, a 28-year-old patient was diagnosed with myelodysplastic syndrome (MDS), a complex malignant hematologic disorder. Initial medical therapy achieved only a partial response; however, in MDS, such responses are often temporary, and durable disease control typically requires definitive curative treatment.

Despite the high-risk nature of the case, a multidisciplinary decision was made to proceed with allogeneic bone marrow transplantation — currently the only treatment modality offering the potential for cure.

Before transplantation, the patient underwent the required conditioning phase, during which high-dose chemotherapy was administered to eradicate the diseased hematopoietic system. This was followed by infusion of healthy hematopoietic stem cells from a fully matched related donor — the patient’s sibling.

A long recovery process now lies ahead. Time is needed for donor cells to engraft and establish a new hematopoietic system, reconstitute immunity, and develop new immunologic memory. This newly formed system must function in harmony with the patient’s body, eliminate residual malignant cells, and provide the patient with an opportunity to move forward beyond the disease.

The transplantation was performed with the support of the state and the VIVA Doctors and Volunteers for Armenia Charitable Foundation. Combined with the high professionalism of the medical team, this support has provided the patient with a renewed chance at life.